Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

This study estimates mean 2017 total and out-of-pocket costs for infliximab and its biosimilar infliximab-dyyb under Medicare Part D.

Saved in:
Bibliographic Details
Published in:JAMA
Main Authors: Yazdany, Jinoos, Dudley, R. Adams, Lin, Grace A., Chen, Randi, Tseng, Chien-Wen
Format: Artigo
Language:Inglês
Published: American Medical Association 2018
Subjects:
Research Letter
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142992/
https://ncbi.nlm.nih.gov/pubmed/30193264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2018.7316
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items